Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data.
Blank-Landeshammer B, Richard VR, Mitsa G, Marques M, LeBlanc A, Kollipara L, Feldmann I, Couetoux du Tertre M, Gambaro K, McNamara S, Spatz A, Zahedi RP, Sickmann A, Batist G, Borchers CH. Blank-Landeshammer B, et al. Among authors: mcnamara s. Cancers (Basel). 2019 Dec 1;11(12):1907. doi: 10.3390/cancers11121907. Cancers (Basel). 2019. PMID: 31805664 Free PMC article.
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.
Couëtoux du Tertre M, Marques M, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, Higenell V, Izzi L, Gambaro K, Hoffert C, Srivastava A, Spatz A, Rousseau C, McNamara S, Cohen V, Batist G, Agulnik J. Couëtoux du Tertre M, et al. Among authors: mcnamara s. Mol Cancer Ther. 2019 Sep;18(9):1628-1636. doi: 10.1158/1535-7163.MCT-19-0105. Epub 2019 Jun 26. Mol Cancer Ther. 2019. PMID: 31243098 Clinical Trial.
Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.
Couëtoux du Tertre M, Marques M, McNamara S, Gambaro K, Hoffert C, Tremblay L, Bouchard N, Diaconescu R, Blais N, Couture C, Pelsser V, Wang H, McIntosh L, Hindie V, Parent S, Cortes L, Breton YA, Pottiez G, Croteau P, Higenell V, Izzi L, Spatz A, Cohen V, Batist G, Agulnik J. Couëtoux du Tertre M, et al. Among authors: mcnamara s. Clin Proteomics. 2020 Feb 7;17:5. doi: 10.1186/s12014-020-9269-6. eCollection 2020. Clin Proteomics. 2020. PMID: 32055239 Free PMC article.
Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer.
Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, Srivastava A, Hébert S, Samson B, Lespérance B, Ko YJ, Dalfen R, St-Hilaire E, Sideris L, Couture F, Burkes R, Harb M, Camlioglu E, Gologan A, Pelsser V, Constantin A, Greenwood CMT, Tejpar S, Kavan P, Kleinman CL, Batist G. Gambaro K, et al. Among authors: mcnamara s. Clin Transl Med. 2021 Apr;11(4):e401. doi: 10.1002/ctm2.401. Clin Transl Med. 2021. PMID: 33931971 Free PMC article.
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.
Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M, St-Hilaire E, Vincent F, Carrier J, MacKay H, Provencher L, Boudreau D, Hamilou Z, Saad F, Ferrario C, Batist G, Marques M. Gambaro K, et al. Among authors: mcnamara s. J Pharm Pharm Sci. 2023 Dec 13;26:12078. doi: 10.3389/jpps.2023.12078. eCollection 2023. J Pharm Pharm Sci. 2023. PMID: 38152647 Free PMC article.
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.
Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Hoffert C, Srivastava A, Schab A, Alcindor T, Langleben A, Sideris L, Abdelsalam M, Tehfe M, Couture F, Batist G, Kavan P. Gambaro K, et al. Among authors: mcnamara s. Int J Mol Sci. 2023 Dec 19;25(1):43. doi: 10.3390/ijms25010043. Int J Mol Sci. 2023. PMID: 38203214 Free PMC article. Clinical Trial.
Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits.
Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M, Johnson NA, Deyell RJ, Rassekh SR, Morin RD. Alcaide M, et al. Among authors: mcnamara s. Sci Rep. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2. Sci Rep. 2017. PMID: 28874686 Free PMC article.
363 results